Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:EQ NASDAQ:FNCH NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$0.71+4.6%$2.16$0.61▼$29.40$4.63M1.072.17 million shs571,180 shsEQEquillium$0.50-10.5%$0.39$0.27▼$1.50$19.75M1.158.33 million shs533,855 shsFNCHFinch Therapeutics Group$12.45+0.1%$12.94$2.80▼$15.85$19.99M1.192,035 shs2,622 shsRLMDRelmada Therapeutics$0.59-2.4%$0.65$0.24▼$3.98$19.98M0.66195,476 shs80,531 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap+4.58%-3.92%-66.12%-77.02%-92.02%EQEquillium-10.45%-30.25%+46.90%+25.84%-32.53%FNCHFinch Therapeutics Group0.00%-0.20%-4.27%-7.81%+288.91%RLMDRelmada Therapeutics-2.41%-0.51%-4.07%+39.89%-81.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBRIACELL THERAP1.6346 of 5 stars3.52.00.00.01.40.00.6EQEquillium2.8448 of 5 stars3.24.00.00.02.91.70.6FNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AN/AN/AN/ARLMDRelmada Therapeutics4.5355 of 5 stars3.15.00.04.40.64.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBRIACELL THERAP 3.00Buy$32.004,376.78% UpsideEQEquillium 2.33Hold$3.00505.82% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.25Hold$5.00751.21% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBRIACELL THERAPN/AN/AN/AN/A($2.20) per shareN/AEQEquillium$41.10M0.43N/AN/A$0.54 per share0.92FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBRIACELL THERAP-$4.79M-$8.320.00N/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)EQEquillium-$8.07M-$0.390.00N/AN/A-19.62%-74.34%-46.75%8/14/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ARLMDRelmada Therapeutics-$79.98M-$2.510.00N/AN/AN/A-192.66%-157.42%N/ALatest BCTX, RLMD, EQ, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A6/13/2025Q3 2025BCTXBRIACELL THERAP-$1.76-$1.64+$0.12-$1.64N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBRIACELL THERAPN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBRIACELL THERAPN/A3.413.41EQEquilliumN/A2.702.70FNCHFinch Therapeutics GroupN/A3.873.87RLMDRelmada TherapeuticsN/A5.295.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBRIACELL THERAP15.42%EQEquillium27.05%FNCHFinch Therapeutics Group21.77%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipBCTXBRIACELL THERAP5.73%EQEquillium31.60%FNCHFinch Therapeutics Group44.90%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBRIACELL THERAP86.78 million6.39 millionNo DataEQEquillium4035.72 million24.43 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableBCTX, RLMD, EQ, and FNCH HeadlinesRecent News About These CompaniesRelmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call TranscriptAugust 8 at 2:10 PM | seekingalpha.comRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025July 31, 2025 | globenewswire.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | finance.yahoo.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | globenewswire.comRelmada terminates license agreement for troubled phase 3 depression assetJuly 11, 2025 | fiercebiotech.comFDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of DirectorsJuly 9, 2025 | globenewswire.comRelmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder CancerJune 17, 2025 | quiverquant.comQRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyJune 17, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in StockMay 21, 2025 | insidertrades.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesFigma's Wild IPO Ride: Is the Stock's Premium Price Justified?By Jeffrey Neal Johnson | August 5, 2025View Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?AI Chip Arms Race: 3 Must-Watch Equipment StocksBy Chris Markoch | July 10, 2025View AI Chip Arms Race: 3 Must-Watch Equipment StocksShield Your Portfolio From Aug. 1 Tariffs With This Low-Vol ETFBy Jordan Chussler | July 15, 2025View Shield Your Portfolio From Aug. 1 Tariffs With This Low-Vol ETFAmazon Takes an Equity Stake in IonQ—Any Upside Potential?By Gabriel Osorio-Mazilli | August 8, 2025View Amazon Takes an Equity Stake in IonQ—Any Upside Potential?AES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerBy Leo Miller | July 14, 2025View AES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerBCTX, RLMD, EQ, and FNCH Company DescriptionsBriacell Therap NASDAQ:BCTX$0.71 +0.03 (+4.58%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.72 +0.00 (+0.03%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Equillium NASDAQ:EQ$0.50 -0.06 (-10.45%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.49 -0.01 (-1.45%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Finch Therapeutics Group NASDAQ:FNCH$12.44 +0.02 (+0.12%) As of 08/7/2025 03:55 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$0.59 -0.01 (-2.41%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.62 +0.03 (+4.70%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
